18F-DCFPyL PET/CT in the Detection of Prostate Cancer at 60 and 120 Minutes: Detection Rate, Image Quality, Activity Kinetics, and Biodistribution
Open Access
- 27 April 2017
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 58 (11) , 1797-1804
Abstract
Introduction: There is increasing interest in PET/CT with PSMA tracers for imaging of prostate cancer due to higher detection rates of prostate cancer lesions as compared to PET/CT with choline. For 68Ga-PSMA-11 tracers, late imaging at 180 min post injection (p.i.) instead of imaging at 45-60 min p.i. improves detection of prostate cancer lesions. For 18F-DCFPyL improved detection rates has recently been reported in a small pilot study. In this study, we report the effects of PET/CT imaging at 120 minutes p.i. of 18F-DCFPyL in comparison to images acquired 60 minutes p.i. in a larger clinical cohort of 66 consecutive patients with histopathologically proven prostate cancer. Methods: Images were acquired 60 and 120 min p.i. of 18F-DCFPyL. We report the positive lesions specified for anatomical locations (prostate, seminal vesicles, local lymph nodes, distant lymph nodes, bone and others) at both time points by visual analysis, the image quality at both time points and a semi-quantitative analysis of the tracer activity in both prostate cancer lesions as well as normal tissues at both time points. Results: Our data shows a significantly increasing uptake of 18F-DCFPyL between 60 and 120 min p.i. in 203 lesions characteristic for prostate cancer (median 10.78 vs 12.86, pConclusion: Image acquisition of 18F-DCFPyL PET/CT at 120 min p.i. yields a higher detection rate of prostate cancer characteristic lesions as compared to images 60 min p.i.. Further studies are needed to elucidate the best imaging time point for 18F-DCFPyL.Keywords
This publication has 34 references indexed in Scilit:
- Utility of Choline Positron Emission Tomography/Computed Tomography for Lymph Node Involvement Identification in Intermediate- to High-risk Prostate Cancer: A Systematic Literature Review and Meta-analysisEuropean Urology, 2013
- 2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate CancerClinical Cancer Research, 2011
- Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancerCancer, 2010
- Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancerThe Prostate, 2009
- N-[N-[(S)-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl-l-Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate CancerClinical Cancer Research, 2008
- A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancerThe Prostate, 2006
- Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen:In vivoImaging in Experimental Models of Prostate CancerClinical Cancer Research, 2005
- Is prostate-specific membrane antigen a multifunctional protein?American Journal of Physiology-Cell Physiology, 2005
- A Novel Cytoplasmic Tail MXXXL Motif Mediates the Internalization of Prostate-specific Membrane AntigenMolecular Biology of the Cell, 2003
- A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urineThe Prostate, 2000